Physician profile
Robert J Breiman
NPI 1831285725
$936.75
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $760 · 2020: $177.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $171.20 | 2019-2020 | |
| Allergan, INC. | $165.30 | 2019-2020 | |
| Glaxosmithkline, LLC. | $137.02 | 2019-2020 | |
| Amgen INC. | $125.00 | 2019 | |
| Amarin Pharma, INC. | $125.00 | 2019 | |
| Pfizer INC. | $47.91 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.25 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $33.97 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.81 | 2019 | |
| Sanofi Pasteur INC. | $22.26 | 2019 | |
| Novo Nordisk INC | $19.70 | 2019 | |
| Ironshore Pharmaceuticals INC. | $14.32 | 2019 | |
| Lilly USA, LLC | $11.01 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Breiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.